Prevention of liver cancer in chronic liver disease: An experimental study of sodium selenite and rat hepatocarcinogenesis by Erkhembayar, Suvd
 From Division of Pathology, Department of Laboratory Medicine 
Karolinska Institutet, Stockholm, Sweden 
 
 
Prevention of liver cancer in chronic liver disease 
     An experimental study of sodium selenite and rat hepatocarcinogenesis 
Suvd Erkhembayar 
 
 
Stockholm 2011 
 
 
 
  
 
All previously published papers were reproduced with permission from the publisher. 
 
Published by Karolinska Institutet. Printed by [name of printer] 
 
© Suvd Erkhembayar, 2011 
ISBN 978-91-7457-554-5 
  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
To my family with endless love 
  
ABSTRACT 
 
Selenium treatment in supranutritional but subtoxic doses has previously been shown 
to inhibit cell proliferation in preneoplastic lesions in a rat liver carcinogenesis model. 
The mechanisms are not known, but thioredoxin reductase (TrxR1), a seleno-enzyme 
essential for maintaining intracellular redox status and cellular defence against 
oxidative stress might be involved. The aim of this work was to study whether 
selenium affected regenerative liver growth after partial hepatectomy as it did 
neoplastic growth and to study the effect of selenium on TrxR1 expression and 
regulation in regenerative and normal rat liver. To address these questions, we have 
compared the effect of sodium selenite on tumour growth in an experimental rat liver 
model for the development of hepatocellular carcinoma with the effect of sodium 
selenite on regeneration of liver mass after 2/3 partial hepatectomy and the effect of 
10 weeks sodium selenite treatment on normal rats.   
Sodium selenite administered in the drinking water (5µg/ml) reduced the rate of 
tumour growth during progression up to 12 months after initiation, but it did not 
affect gain of liver mass or rate of cell proliferation up to three weeks after 2/3 partial 
hepatectomy. Sodium selenite supplementation at dose levels of 1µg/ml and 5µg/ml 
showed an initial dose dependent increase of blood and liver levels of selenium. At 6 
and 8 weeks, respectively, the selenium concentrations equilibrated regardless of dose 
and with no further accumulation. Sodium selenite did not affect body weight or 
relative liver mass at given doses. 
We also explored whether TrxR1 was a marker of the liver tumour phenotype or if 
the TrxR1 over expression found in liver preneoplasia and neoplasia could be 
explained only by TrxR1 induction in growing cells. We found that from 6 months 
after initiation in the tumour model TrxR1 was only expressed in neoplastic liver 
lesions that showed signs of cell proliferation (bromodeoxyuridine (BrdU) 
incorporation), while remodelling preneoplastic liver nodules that were BrdU 
negative were immunohistochemically negative for TrxR1. Both types of lesions 
were, however, expressing the classical marker of preneoplastic and neoplastic 
nodules, glutathione S-transferase π (GST-π). During liver cell regeneration TrxR1 
was induced at the time of cell proliferation, but was back to background activity 72 
hours after partial hepatectomy. Sodium selenite potentiated this increase in enzyme 
activity. When sodium selenite was given to normal rats over long time TrxR1 
activity was induced in the liver to an extent reflecting the liver selenium levels. 
TrxR1 mRNA was, however, only increased over background at the time when the 
selenium level was increasing. We found that, although TrxR1 did increase to a 
certain extent during cell proliferation, the neoplastic over expression of TrxR1 was 
not correlated to the rate of cell growth in the tumours. Our interpretation of the  
finding that TrxR1 was selectively over expressed  in the growing preneoplastic and 
neoplastic liver lesions  is that TrxR1 is a tumour marker with a higher specificity to 
neoplasia with an increased risk for malignant transformation.    
  
Based on the facts that long-term treatment of selenite did not cause accumulation of 
selenium or selenium toxicity and the fact that selenium inhibited only neoplastic 
growth but not regenerative growth we suggest that selenium is a suitable candidate 
for tumour prevention in patients with chronic liver disease dependent on sustained 
ability of liver regeneration. Furthermore TrxR1 is a histological marker in chronic 
liver disease for liver cancer and liver cancer prestages with a potential to be a marker 
for liver cancer risk.  
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1 LIVER CANCER AS A PREVENTABLE DISEASE.  
 
It is generally agreed that cancer is a preventable disease. Using the knowledge we 
already have the majority of cancer deaths seen today can be avoided. This is 
particularly true for the cancers where we know the major risk factors and causes of 
disease, like liver cancer. The most important tumour preventive action is to avoid 
exposure to known risk factors and to avoid risk behavior. However, this is more 
easily said than done in many countries with a low social-economic status and a poor 
population. In developed countries, on the other hand, this is possible for most 
people. For people already exposed to liver cancer risk factors, as chronic viral liver 
infection diseases, the risk of developing liver cancer can be reduced by active 
treatment of the viral disease. This is expensive and all patients do not tolerate the 
treatment or are not responding to therapy. There is today very little to do for patients 
with multi viral liver infections caused by several viruses or where a combination of 
risk factors exists. Thus there is a demand to obtain a cost-effective tumour 
preventive strategy for HCC.  
The HCC incidence is very high among the population in sub-Saharan Africa and part 
of Asia, particularly Mongolia and China. Lately the occurrence of HCC has been 
shown to increase also in USA and part of Europe, including United Kingdom and 
France. In my home country, Mongolia, the incidence of HCC has been increasing 
tremendously and reaches now 99 cases of primary HCC per 100,000 inhabitants and 
represents the worst HCC threatened part of the world. Most patients will die within a 
year after established diagnosis. HCC is now also affecting patients at younger ages.  
In this thesis I am addressing those patients that have a chronic liver disease and an 
increased risk of liver cancer development. The most prominent risk factors in my 
home country are hepatotropic viruses of type B, C, D and E. In different 
combinations these viruses causes chronic liver damage and ultimately liver cancer in 
patients who fail to clear the viruses after the acute infection and get a persistent 
infection.  Today only a minority of these patients can be successfully treated for 
their chronic liver disease, but for the non-responders and the patients that cannot 
stand or afford the tough and long lasting therapy there is very little else to do, than to 
wait for the cancer to appear. For these people there is a need for markers for early 
detection of liver cancer in stages that can be treated and for methods to reduce the 
risk for cancer development and to reduce tumour growth once it has appeared.  
There is a controversy connected to liver tumour prevention and treatment in patients 
with chronic liver diseases. First of all the protocol has to reduce tumour growth and 
tumour cell proliferation to be tumour preventive. This effect has to be specific for 
the tumour cells and not affect the growth of the non-neoplastic hepatocytes. In 
patients with chronic liver disease the normal hepatocytes are injured and some of 
them are dying reducing the liver function. For the survival of the patients the 
reduced functional mass of the liver has to be compensated by liver cell regeneration, 
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so-called compensatory liver hyperplasia. If this is inhibited the liver function will be 
compromised even further threatening the life of the patient. 
This thesis work is focusing on the clinical dilemma of the patient with chronic liver 
disease using experimental liver models in the rat to study the development of liver 
cancer and the effect of sodium selenite to reduce the appearance or growth of liver 
neoplasia without inhibiting the growth of the normal hepatocytes. I have also 
addressed the search for a biomarker for liver cancer and liver cancer prestages that 
could be helpful in early detection of liver cancer in patients with chronic liver 
disease. Such a marker could be used to find those patients with chronic liver disease 
that have an increased risk of getting liver cancer and select them for a lifelong cancer 
prevention program.   
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2 LIVER CANCER 
 
Hepatocellular carcinoma (HCC) is the most common form of primary liver cancer 
and is the fifth most frequent cancer form and the third most common cause of cancer 
related deaths worldwide [1-2]. Annually about 500,000-1,000,000 new cases of 
HCC occur and 600,000 persons die due to  HCC [3]. The incidence of liver cancer 
and liver cancer related death varies greatly around the world, depending mostly on 
geographic and socio-economic prerequisites in different areas of the world. Regions 
that have higher incidences of viral hepatitis of different types have higher incidence 
of HCC and the incidence varies with the type of virus hepatitis that is dominating in 
the area. Over 80% of the endemic viral infection related HCC occur in sub-Saharan 
Africa and Southeast Asia [4]. In these countries, the incidence is very high, generally 
over 20 cases per 100,000 individuals in the population. The highest incidence is in 
Mongolia with 99 cases per 100,000 individuals.  
In countries, with moderate to intermediate risk, including Italy, Spain, France, 
United Kingdom, the incidence is estimated to be 5-11 cases per 100.000,while the 
lowest incidence is less than 5 cases per 100,000 population is found in United States, 
Canada and  Scandinavia. There are still some areas in the world, where the incidence 
of HCC is not reported [3]. The clinical prognosis for liver cancer is poor, the 5 year 
fatality rate in individuals with established diagnosis of HCC is greater than 95% [5].  
In a global perspective, the incidence of HCC is rising progressively. In United States 
over the last 25 years a 70% increase in HCC cases was reported [6] .Due to the 
spread of HCV and HBV the increase of HCC incidence is also seen in other 
countries including the United Kingdom and Western Europe [7-9].  The incidence of 
HCC increases with age, the highest prevalence occurs among individuals older than 
65 years [10-11]. However during the last decades, an increasing incidence among 
younger adults has been observed[12]. Age specific incidence of HCC varies greatly 
in different parts of the world. Onset of HCC peaks at 40 among West African and 
Mongolian men while the peak age of onset in China is 70-80 [13-14]. Gender can 
also play a role in the risk and outcome of HCC and generally the incidence of cancer 
development among men are three to five fold that in women [15]. The peak age of 
HCC incidence is 5 year earlier in men compared to females [16]. The reason for the 
male predominance of HCC is likely to be multifactorial. The incidence of HBV 
induced HCC is higher among men than the HCV related.  Innate factors are likely to 
be involved in the male predominance of HCC. Testosterone  have been shown to be  
correlated with HCC development [17]. In addition male drink more alcohol and 
smoke more than women do in the areas where liver cancer is endemic. In 
experimental hepatocarcinogenesis there are also gender differences, some of them 
indicating the complexity of the mechanisms in initiation and promotion. In the rat 
liver model used in this thesis, with 2-acetylaminofluorene (2- AAF) as a promoter 
there is a gender difference in promotion but not in initiation. This difference is 
dependent on the lack of a growth hormone dependent sulfotransferase in the female 
 4 
 
liver that is necessary for activation of the promoter [18-21]. In a study on a mice  
liver cancer model an increased expression of  IL-6 in male mice in relation to female 
mice was suggested to explain the male dominance in liver cancer development in the 
model [22]. Interestingly, reduction of IL-6 in male mice prevented liver cancer 
development in 90% of the male mice, while ovariectomy enhanced IL-6 production 
and induced HCC development in female mice.  
 
 
2.1 RISK FACTORS  
Chronic liver injury of different origin constitutes a potential risk for liver cancer 
development. In contrast to many other cancers, the main risk factors for HCC are 
well identified [23-24]. Geographical differences in liver cancer incidence usually 
reflect the main causal factor variations [23]. It has been estimated that approximately 
one third of the world population has been infected by hepatitis B virus (HBV)  and 
that about 350 million people are persistent carriers of HBV[25]. HBV is the most 
prominent risk factor for HCC particularly among the population in Asia and Africa. 
High exposure to aflotoxin B1 and its synergistic action with HBV is making it one of 
the potential risk factors in these areas [26]. About 170 million individuals have been 
infected with hepatitis C virus (HCV) worldwide [25,27]. HCV and other cirrhosis 
inducing factors such as alcohol abuse and heamochromatosis are main causes of 
HCC in western countries and Japan [28]. 20% of individuals with chronic HCV will 
develop cirrhosis and 2,5% develop liver cancer [29].The patients with the highest 
risk of liver cancer are those with chronic HBV infection and liver cirrhosis with 
1,000 fold increased risk compared to healthy individuals [30]. HDV in association 
with HBV will further increase the potential for liver cancer. Coexistence of HBV 
and aflotoxin B1 comprises 5-10 folds higher risk for HCC development compared 
with exposure to only one of these factors [31]. HCC in chronic HCV infected 
patients is increased 20-fold compared to non-infected individuals [32]. Individuals 
with functional polymorphisms of alcohol metabolizing enzymes, alcohol 
dehydrogenase (ADH2) and aldehyde dehydrogenase (ALDH2)  are more vulnerable 
to alcohol abuse and alcohol dependence. Consequently, heavy alcohol consumption, 
≥80mL daily will increase the risk 5 fold and in combination with viral infection and 
related cirrhosis the risk for HCC will be increased even more.  Moreover, HCC 
develops in the setting of several metabolic liver diseases, including  
heamochromatosis (HH) , Wilson’s disease and nonalcoholic steatohepatitis (NASH), 
primary biliary cirrhosis (PBC) and primary sclerosing  cholangitis (PSC) [33].  
Diabetes mellitus, (insulin or non-insulin dependent)  is another metabolic disease 
which increases 4 fold the risk for HCC [34]. Practically, all liver cirrhosis inducing 
conditions belong to the important risk factors for HCC development  as in about 
80% of the liver cancer patients, HCC arises in a cirrhotic liver as an ultimate 
complication of the chronic liver disease [35].  The lifetime risk of getting HCC in 
patients with HH is increased up to 200 fold, particularly if it is complicated by 
cirrhosis [36-38]. The overall risk  for patients with primary biliary cirrhosis (PBC)  
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to develop HCC is also   20-fold increased [39]. Non-alcoholic fatty liver disease 
(NAFLD) has higher prevalence in developed countries and is related to obesitas with 
an increased cancer risk in the patients developing NASH and cirrhosis. Up to 1/3 of 
individuals with NASH develop cirrhosis within 10 years [40].  NAFLD accounts for 
30-40% of all cases of HCC among patients with established diagnosis of cryptogenic 
cirrhosis [41].  Thus, the increasing incidence of obesity, particularly in USA and 
lately in Western Europe will lead to an increase of HCC incidence due to fatty liver 
disease.   
 
 
 
2.2 DIAGNOSIS AND CLINICAL COURSE 
The patients diagnosed with liver cancer are sometimes known by the health care 
system because of their chronic liver disease but sometimes the tumour is found at 
medical examinations for other purposes. The symptoms of the cancer itself are very 
sparse and non-specific. The liver has a huge capability to compensate for the 
presence of the lump, unless it is not interfering with the central bile ducts causing 
jaundice. Ultrasound and CT-examinations showing hypervascularized mass lesion of 
>2 cm in diameter usually in cirrhotic liver with an increased serum AFP level of 
>400mg/L is considered to be diagnostic for HCC [42]. 
The clinical course and outcome of liver cancer is dependent on different factors, 
such as age, gender, time point when initial infection had occurred and duration and 
activity of underlying disease. Presence of co-existing diseases and immune status are 
other important factors that have impact on the outcome.  Due to lack of specific 
clinical symptoms and reliable markers for early stages and prestages of the disease 
HCC is usually detected in advanced stages when patients become symptomatic. At 
such late stages when liver functions are impaired and complications have appeared it 
is usually little chance to achieve prolonged survival and a successful outcome with 
available treatment options. The overall worldwide liver cancer survival rates indicate 
that only 5% of liver cancer patients will survive 5 year after established diagnosis[5]. 
Patients usually die within 1 year after established HCC and the vast majority of these 
patients are resided in that part of world, where HBV and HCV infections are 
endemic.  
However, nowadays in wealthy societies, an increasing number of patients with 
chronic liver disease are followed up and are diagnosed with an early stage HCC 
when the patients are lacking cancer related symptoms and the liver function is not 
impaired to a critical extent [43]. Consequently, the final outcome will be improved 
from early detection and management.  In cases where the cancer can be surgically 
removed 75% of the patients will survive for 1 year and 60-70% for 5 year with 
recurrence of 50-70% of patients at 5 years [44]. In selected materials 5-year survival 
up to 70% and 10-year survival up to 30% have been published [45-46]. Liver 
transplantation results have been improving due to better immunosuppressive therapy 
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and development of better diagnostic tools. The overall recurrence rate after 
transplantation is still 40% within 5 years mainly due to remaining cancer cells after 
surgery and the underlying chronic liver disease  especially in patients with HCV 
caused primary HCC [47-48]. 
However, better results can be achieved by improved early detection and pre and post 
surgical management. With improved early term management, patient survival rate at 
10 years after liver transplantation  exceeded 70% in a recent study [49]. The 
presence of HBeAg and its seroconversion is one of most decisive survival factors 
and significantly correlate to overall survival after curative resection for HCC.  
 
2.3 LIVER CANCER TREATMENT 
Treatment of HCC depends on extent of tumour burden and severity of underlying 
diseases. There are several potentially effective treatment options available for HCC, 
including liver resection and liver transplantation. However due to the lack of donor 
organs the latter is restricted. Overall liver cancer treatment can be divided into 
curative and non-curative treatment protocols. 
 
 
2.3.1 Surgical radical resection  
Surgical resection is the most commonly used curative therapeutic option. 
Immediately after the surgical resection the liver regeneration takes place in the 
remaining liver and the functional liver mass is reestablished. Meanwhile, the 
remaining liver mass should suffice to support adequate liver function under 
circumstances of an increased workload.  Thus well-selected patients in accordance to 
stages of cirrhosis, tumour size, vascular invasion and intrahepatic dissemination are 
the decisive factors for outcome. Patients with one large solid tumour without or with 
early cirrhosis and preserved liver function usually benefit from surgical radical 
resection.  
 
2.3.2 Liver transplantation  
Liver transplantation (LT) is an effective therapeutic option in patients with advanced 
HCC. In addition patients with early HCC associated with severe cirrhosis are one of 
the most suitable groups of candidates for LT.  According to the Milan criteria, the 
most used selection criteria, patients with liver cirrhosis who have single tumour 
nodule <5cm or a maximum of three tumour nodules each < 3cm without gross 
vascular invasion is acceptable for LT [50]. Other selection criteria try to cover more 
patients outside of Milan criteria and allow patients with bigger tumours for 
transplantation. The UCSF criteria allows LT for more advanced tumours but with 
similar results as with the Milan criteria, namely single lesion <6,5cm or up to 3 
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lesions, each <3cm with total of <8cm [51-52]. Moreover, LT  is restricted due to a 
number of factors, including  limited access to graft and graft rejection [53].  
 
2.3.3 Locoregional therapy 
The third most commonly used treatment option in HCC is locoregional therapy. 
Locoregional therapy comprises several treatment approaches focused on the tumour 
site, including ablation and transarterial chemoembolization (TACE).  In non-
resectable HCC, local ablation is considered to be the best suitable medical option 
[54]. The ablation can be performed by modification of the temperature in neoplastic 
lesions by using radio-frequency ablation (RFA), microwave or laser ablation, or 
cryoablation or by using chemical substances, e.g. alcohol. The main ablation now 
used is RFA which have been shown to be more effective than percutaneous ethanol 
injection (PEI), particularly in tumours <4cm [55].  In PEI, ethanol will be introduced 
intra tumourally and it causes necrosis in tumour cells and thrombosis in tumour 
vessels. In TACE, chemotherapeutic agents such as doxorubicin and cisplatin are 
injected via the hepatic artery or blood supplying arteries directly into the tumour.  
 
 
2.3.4 Chemotherapy 
The effect of the systemic chemotherapy in HCC is limited. Both response rate and 
duration is short. Nowadays, no single or combined chemotherapy regimen has been 
found yet to be effective in HCC [56]. The main obstacles for systemic chemotherapy  
in HCC include chemoresistance of HCC cells, and intolerance to the cytotoxic drugs 
in cirrhotic patients [57]. 
Doxorubicin is the most used single effective agent in HCC  [58].  
 
 
2.3.5 Molecular targeted therapy 
Molecular targeted therapies directed on distinct signal pathways involved in 
development and progressions of HCC have been investigated in several phase II and 
III studies. Phase II studies have recently been performed on drugs blocking 
epidermal growth factor receptor (EGFR), such as erlotinib and lapatinib, vascular 
endothelial growth factor (VEGF) inhibitor, bevacizumab, and multiple kinase 
inhibitor, sunitinib.  
HCC is one of most vascularised solid tumours and the vascular endothelial growth 
factor (VEGF) is a target for anti-angiogenitic drugs such as bevacizumab and 
sorafenib have been used with promising effects. Sorafenib, a multikinase inhibitor, is 
directed against several targets, including VEGF and Ras to inhibit tumour-cell 
proliferation and tumour angiogenesis. 
Llovet’s phase III clinical trial and the Asia-Pacific phase III sorafenib study have 
shown that sorafenib adds three months to the lifespan of late stage HCC patients 
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with well preserved liver [59-60].  Based on these results, sorafenib has so far been 
approved by FDA as the only molecular targeted drug for treatment of late HCC.  
Regardless, the type of available treatment choices, one of the most important factors 
for final outcome is the proper selection of patients. The 5-year survival rate exceeds 
70% in well selected patients upon radical resection and this figure is markedly 
reduced in case of improper selection. In addition, in more than 80% of the patients 
recurrence will appear during follow-up [46,61]. 
Due to liver tumour heterogeneity and drug resistant liver tumour cells, the 
prevention of recurrences has been enduring difficulties. Previous attempts to 
diminish recurrence rate after resection by preoperative chemoembolization and 
chemotherapy had no or little effect, whereas radiation therapy and immunotherapy 
have shown some promising effect. 
As mentioned above encouraging results of   LT by Milan criteria were >70% 5 year 
survival rates and recurrence rates <15% [52,62]. Moreover, in patients who already 
had been resected due to solidatory HCC, LT is possible in cases with high risk of 
recurrence [63]. A recent study with split LT (SLT= the donor liver is split to two 
recipients) in adults and children has shown a promising result regarding the patient 
long-term survival. In this study, the 1 and 5 years overall survival in adults and 
children were 75%/66% and 84% /72% respectively [64].  Thus, SLT might enable to 
overcome the restriction due to the organ shortage and reduce the waiting list and 
mortality rate. In addition, the combination of TACE and PEI resulted in better 
survival rates than single treatment with TACE or PEI in non-resectable patients [65-
66].  Furthermore, TACE can be used in order to stabilize the tumour during the time 
when patient is waiting for LT and/or to diminish the tumour burden with a purpose 
of making the patient eligible for transplantation later on. TACE causes tumour 
necrosis in more than 50% of cases and is generally well tolerated [67].   
Finally, the recent advances in pre- and intra-operative patient management and 
improved post-operative care and prevention of infection and rejection have been 
providing a better outcome.   
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3 TUMOUR DEVELOPMENT IN THE LIVER 
 
Carcinogenesis is generally described as a multistep process that can be divided into 
separate processes of initiation, promotion and progression. These processes have been 
defined and described in experimental models but can also be recognized in human 
cancer development in the liver, although overlapping processes and the underlying 
chronic liver disease that is usually seen make the steps less well distinguishable.   
In this thesis we have worked with a synchronized rat liver model where initiation, 
promotion and progression can be separated and defined [68].(See fig 5) 
Briefly the multistep hepatocarcinogenensis process is described in the following (See 
fig1). In a situation with a chronic liver disease creating an oxidative, necrogenic 
environment rare cells might be initiated in a process involving DNA alterations that by 
DNA replication results in a mutation or mutation like event. This mutation renders 
these rare cells or some of these cells capabilities to grow under circumstances where 
normal cells are not growing or allowed to grow by cellular defense mechanisms. 
Promotion of the growth of these initiated cells is a selection of cells that are able to 
grow in an environment that is toxic/mitoinhibitory for most hepatocytes. The 
hepatocytes selected to grow in the liver will by clonal expansion form a population 
that in the model is defined as a preneoplastic liver nodule. This clonal adaptation is 
beneficial for the organism and helps the animal to survive in the acute toxic situation. 
The preneoplastic growth is dependent on the presence of the promoter or a promotive 
environment creating the selective pressure that favors the cells that have acquired a 
resistance to the mitoinhibitory effect of the promoter. These cells are therefore not 
defined as tumour cells but rather as cells adapted to a harsh environment by clonal 
adaptation. The growth advantage acquired by these cells however has a price. Being 
able to grow under circumstances that are growth-inhibitory for normal hepatocytes and 
oxidative, exposes these cells to further risks for genetic alterations and mutations. The 
cost is a reduced cellular defense and an unstable genome. The probability for the 
second mutational event dependent on environmental stress, the size of the 
preneoplastic population and the growth rate therefore increases. These factors are 
related and not independent from each other.  
In the model the second mutation represents the events necessary for the preneoplastic 
cell to acquire a neoplastic phenotype and express the neoplastic growth advantage in 
the absence of the selective pressure from the promoter. This autonomously growing 
cell will by clonal expansion form the tumour that by further alterations in the unstable 
genome progress to an invasive malignant tumour with metastatic properties.  
The phenotypic alterations acquired by the preneoplastic and neoplastic hepatocytes 
are multigenetic and very complex rendering them able to grow in a toxic 
environment [69]. The drug metabolizing systems are changed in a direction making 
the cells more resistant to toxicity and oxidative stress. The phase I, cytochrome P450 
catalyzed drug activation process, is slowed down, while the phase II conjugating 
processes are increased. As a consequence of these alterations fewer reactive 
intermediates will form and bind to cellular macromolecules. In addition, water-
soluble and lipid-soluble antioxidants are heavily increased as are certain antioxidant 
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regenerating enzymes, like thioredoxin reductase, regenerating a large number of 
antioxidants, including the active lipid-soluble, membrane associated antioxidant 
ubiquinol from the oxidized form ubiquinone. Another important early alteration is 
inactivation of the tumour suppressor P53, not by mutation, but by an inability to 
enter the nucleus [70]. The inactivation of P53 will permit cell proliferation although 
the DNA is compromised. 
  
 
 
 
Fig 1.   Schematic presentation of the multistep process of hepatocarcinogenesis. 
 
 
The key factors in the carcinogenic process are genetic alterations and growth. The 
genetic alterations are dependent on the oxidative environment and the genetic 
instability caused by ineffective processes defending the genome. In the clinical 
situation regenerative growth is triggered by hepatocellular malfunction reducing the 
functional liver mass. In human liver cancer development usually the cause of disease 
lead to chronic liver damage with hepatocyte injury, activation of Kupffer cells, which 
affect the stellate cells so they transform into myofibroblasts and deposit collagen.  The 
fenestration of the endothelial cells disappear and the basal membrane of the sinusoids 
appear as a continuous, capillary basal membrane reducing the exchange between 
hepatocytes and blood. This functional insufficiency will be compensated by increased 
cell proliferation. (See fig 2) 
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Fig 2. Schematic presentation of cellular changes in chronic liver cell injury 
causing liver cirrhosis, sinusoidal capillarisation and compensatory cell 
proliferation and its relation to tumour development.  
 
Chronic liver injury with compromised liver function creates a need for chronic repair 
processes with chronic regeneration. In this complex environment the oxidative 
components as well as cell proliferation coexists and fulfil the prerequisites for liver 
tumour development. In fact, also in human hepatocarcinogenesis liver lesions 
comparable to preneoplastic foci/nodules, neoplastic nodules/adenoma and 
hepatocellular carcinoma are seen. The whole series of events, from the initial infection 
or initial exposure to etiological agents until development of clinically detectable 
malignant tumour usually takes 5-20 years [71].  
Most human liver cancers are developed in a cirrhotic liver. Due to failed viral 
clearance and consequent interaction of viral and host immune reactions a chronic 
necroinflammatory hepatitis appears. The carcinogenic process progresses in these 
livers in parallel with the progression of the chronic hepatitis. The risk to develop liver 
cancer increases with the increasing activity of viral replication and grade of hepatitis. 
Understanding the causes of liver cancer as well as mechanisms and stages of cancer 
development is important for the design of tumour preventive strategies. 
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4 LIVER CANCER PREVENTION 
 
Liver cancer development has a long duration and the risk factors are often known as 
is the liver injury itself. Preventive strategies can be applied in all stages of the 
disease from the early stages of development of tumour prestages including initiation 
and promotion through progression and malignant transformation to further 
progression to an invasive tumour that spreads and metastasizes. The overall 
prevention can be divided into three parts, primary, secondary and tertiary. The 
primary prevention is based on strategies to avoid exposure to risk factors and to 
correct risk behaviour. In secondary prevention of liver cancer the chronic disease is 
already established and the focus is on reducing the risk of tumour development 
interfering with the mechanisms of the necro-inflammatory liver cell damage 
compromising the functional liver mass. In tertiary prevention the neoplastic disease 
of the liver is diagnosed and the aim will be to eliminate the tumour and to reduce the 
growth rate of the residual neoplasia after treatment and to prevent recurrence of 
disease in the liver or elsewhere in the body. A reduced growth rate will considerably 
impair progression of disease and significantly prolong survival. 
Primary prevention eliminates or reduces the exposure to the causal factors for HCC 
and includes reduction of exposure to hepatitis virus, vaccination against hepatitis virus 
disease, refrain from alcohol, avoidance of exposure to aflatoxin, body weight control 
etc. Hepatitis of importance for the development of liver cancer is usually spread as a 
blood-borne infection via the skin, mucus membranes or directly into the blood. It is 
therefore important to reduce the exposure to the viruses that can be spread through 
infected syringes and blood transfusion, but also unprotected sexual intercourse with 
infected persons etc. Screening of blood donors for blood transfusions for hepatitis 
visuses and the use of disposable syringes in the health care system are important 
contributions for reduction of virus spread.  Screening of blood donors for HCV was 
introduced in 1990. The first vaccine against HBV was introduced on the market 1981. 
Universal vaccination against HBV was started during 1984-1986 in countries with 
endemic disease, including Taiwan and Mongolia.  In those countries and in other 
countries where hepatitis is an endemic disease and where HBsAg positive carriers are 
usually infected by the vertical transmission route during birth or in early childhood 
HCC usually develops at the age of 40 or younger and is usually detected late when 
treatment is not effective.  The protective efficiency of HBV vaccination has been in 
the range of 90% to 95% from HBV vaccination programs in Korea, China and 
Taiwan, which is very promising for HCC prevention. Moreover infant mortality in 
fulminant hepatitis and childhood HCC incidence decreased in Taiwan. As a result of 
the nationwide vaccination of infants, the prevalence of HBV carriers in childhood is 
almost eradicated, decreasing from 15% to 1%. Consequently the HCC incidence in 
Taiwan decreased by 60% [72].   Nowadays vaccination against HBV is available for 
all infants. Even HBV negative adults have now the possibility to get vaccine. In spite 
of the success of HBV vaccination and the noticeable reduction of the global burden of 
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HCC among vaccinated children and younger adults, an increasing rate of HCC is seen 
in individuals over 30 years of age.  
Due to the viral genetic heterogeneity of hepatitis C virus HCV vaccination  has been 
much more complicated [73], but new strategies are developing.  In contrast to HBV, 
HCV is rather variable and prone to mutation, which makes it similar to HIV.  A DNA 
vaccine made of the more conserved part of the HCV genome, NS3, is under 
investigation. By a new delivery technique the DNA vaccination improved its  
efficiency of the immune based attack to combat HCV [74]. 
In many parts of the world aflatoxin is a frequently contaminant in the food. Aflatoxin 
by itself but also because of its synergistic action with HBV for induction of HCC 
makes it an important target to prevent liver cancer development. Aflatoxin is a fungal 
toxin which can be produced in any foodstuff.  Contamination of basic food staples 
such as corn, nuts and rice is a major problem in developing countries. Moisture 
content in the crop, air humidity and temperature are main factors for fungal growth 
and aflatoxin production. The most important actions to reduce aflatoxin exposure in 
the population is to invest in proper facilities for food storing and processing in the 
entire chain of events from the fields, warehouses, stores and all the way to the plates. 
Regular test for contamination have to be performed and contaminated food should not 
be distributed and consumed. 
Alcohol consumption is a well known risk factor for liver cancer in all societies.  
Drinking excessive amount of alcohol and alcohol abuse is linked to HCC, particularly 
in combination with other liver risk factors or diseases. Among many studies all over 
the world a recent Japanese study on association of alcohol consumption and HCC 
development concluded that the avoidance of heavy alcohol drinking (≥69.0 g 
alcohol/day) in men and moderate drinking (≥23.0 g alcohol/day) in women reduced 
the risk of HCC [75]. Policymakers and health care providers should be aware of the 
importance of making public health recommendations on alcohol drinking and the 
consequences of heavy drinking habits. In Sweden, alcohol purchases and trade is 
prohibited for people under age of 21 and alcohol is provided only by Systembolaget.  
In addition it is forbidden to advertise beverages with an alcohol content exceeding 15 
volume percent. It is becoming increasingly difficult to monitor and control alcohol 
consumption in a modern and open society.   
 
It has been increasingly clear that physical activity and a well balanced dietary intake 
are important factors for the primary prevention of cancer, although the evidence for 
causal association between physical activity and cancers ranges from convincing to 
insufficient regarding different cancer sites. 
Insulin resistance and obesity, particularly among children is increasing in USA and 
recently in all Western countries. Obesity and diabetes mellitus are often associated with 
NAFLD and NASH and ultimately increase the risk for HCC development. 
Observational studies have shown that food rich in fruits and vegetables protects against 
cancer since they contain essential micronutrients with antioxidant potential, including 
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selenium, but the  specific cancer protective elements in this diet rich in fruit and  
vegetables are still not identified [76]. Study on relationship between different 
antioxidant supplementations and tumour prevention has not been consistent and in the 
case of beta-caroten showed an inverse effect [77-79]. In one Chinese study including 
selenium a cancer preventive effect was seen [80]. In a recently published meta analysis 
of 67 studies performed on more than 230,000 individuals supplemented with Vitamin 
A, C, E, betacaroten and selenium the authors concluded that antioxidants increased the 
cancer risk, especially Vitamin A, betacaroten and Vitamin  E but not selenium [81-82].  
In diets rich in fruits the fructose consumption is increased and in contrast to glucose, 
fructose is entirely entering into the liver and causes de-novo lipogenesis and is thereby 
implicated in NASH development [83].  In addition, daily fructose consumption has 
shown to prompt  fibrosis and increase liver inflammation in patients with NAFLD 
[84]. 
Secondary prevention is focused on the interference with the pathogenetic mechanisms 
of HCC development. During secondary prevention it is important to treat the patients 
with chronic liver disease for their specific disorder. In addition to alcohol restriction 
and diet adjustments it is important for patients with viral hepatitis to reduce the viral 
load and the necro-inflammatory reaction in the liver using antiviral and anti-
inflammatory therapy. To achieve a sustained virological response on antiviral 
treatment and keep the viral replication at a low level over time is the goal for these 
patients. The inflammatory response in the virus infected liver can also be treated by a 
combination of antiviral therapy and interferon. There are seven FDA-approved 
medications in use for the management of HBV infections: two formulations of 
interferon (IFN), conventional IFN and PEG-INF and five nucleoside analogues 
(lamivudine, adefovir dipivoxil, entecavir, telbivudine and tenofovir disoproxil) [85]. 
This treatment strategy has proved successful reducing the viral load as well as the 
inflammation and surprisingly also reducing the amount of fibros tissue in liver fibrosis 
and cirrhosis [86]. Even when tumour prestages and tumours have developed the 
progression to cancer can be stopped or slowed down. Antiviral treatment to reduce the 
risk of developing liver cancer in patients with HCV chronic viral infections has also 
been improved. Sustained viral response up to 75% was achieved by a combined 
antiviral treatment. Antiviral treatment to reduce the recurrence of HCC after diagnosis 
and initial therapy of HCC can also be included as a strategy for secondary prevention.  
Patients with hemochromatosis (HH), a hereditary disease in iron metabolism, causes 
chronic liver disease with 200 fold increased risk for liver cancer. If HH is diagnosed 
early and treated soon after confirmed diagnosis the increased risk for liver cirrhosis 
and liver cancer can be eliminated by simply reducing the iron load by venesection on a 
regular basis. 
The aim of tertiary prevention is to prolong the life of patients with an established and 
diagnosed cancer by removal of the cancer or by other treatments reduce the growth 
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rate of the already established tumour. For the principles and tools for tertiary 
prevention of liver cancer I refer to the chapter of liver cancer treatment above.  
A successful tumour prevention strategy has to take all factors into consideration and 
include knowledge of epidemiology, mechanisms of tumour development, early tumour 
diagnosis and tumour treatment. In this perspective the knowledge of the mechanisms 
of tumour development and the appearance and detection of prestages and early stage 
cancers are very important. 
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5 CLINICAL RELEVANT MARKERS FOR 
PRENEOPLASIA AND NEOPLASIA 
 
There is an urgent need for clinically relevant markers for liver cancer and for liver 
cancer risk. An optimal marker will provide us with a non-invasive tool not only for 
early diagnosis but also for estimation of cancer risk on an individual basis. The marker 
or marker panel should provide information on the activity of the underlying chronic 
liver disease, the existence of liver cancer prestages as well as early liver cancers. With 
the help of such a tool the patients at risk could be found and subject to intense follow 
up, prevention strategies and early treatment. Moreover, with an easily available and 
relevant marker it will be easier to estimate tumour burden, to follow up on treatment 
response and to detect relapse and minimal residual disease (MRD).  
The activity of the liver injury is playing a decisive role for liver cancer development. 
Nowadays, there are no good, reliable markers to identify and follow the activity of the 
liver disease, the grade of liver injury and it’s progression. Blood levels of enzymes and 
compounds reflecting liver function and liver damage are helpful but need to be 
complemented with markers for the inflammation and the deposit of fibrous tissue in 
the liver. Core liver biopsies provide the clinician with information of the liver damage 
and the activity of the disease and serve as a basis for estimation of prognosis, but the 
risk for complications when a sick liver is punctured with a 1.2 mm needle limits its 
value as a marker for repeated follow up of disease. The histological examination of 
core biopsies is used for estimation of the extent of liver cell necrosis, the activity of 
inflammation and the stage of fibrosis. Core needle biopsies are considered to be the 
golden standard to determine the liver disease as well as to diagnose liver cancer, but 
the method is not patient friendly. The risk for profuse bleeding and bile leakage and 
tumour dissemination along the biopsy tracts are most prominent risks for this method 
and explain why it is used with restriction in clinical centres for diseases in the liver. 
Fine needle aspiration biopsies have been suggested for studies of the inflammatory 
infiltrate in hepatitis patients, but as of today it is not used in the clinic, although the 
intrahepatic inflammatory cells could provide clinically relevant information on the 
activity of a necro-inflammatory disease in the liver [87-88].   
The currently recommended and the only clinically used predictor in the blood of HCC 
is serum α-fetoprotein (AFP). An increased serum level of AFP, > 20 μg/L, initiates 
further investigation in order to exclude malignancy. However, AFP is neither a 
sensitive nor a specific marker for liver malignancy as it can be negative in up to 40% 
of small HCC and is increased during pregnancy and in benign liver diseases as well. 
AFP is also increased in other malignancies, including stomach and pancreatic cancers. 
In addition the tissue AFP is uninformative. Seromarkers for HBV and HCV is not very 
informative as a clinical marker for a patient with a known chronic liver disease. 
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5.1 THIOREDOXIN REDUCTASE 1 AS A POTENTIAL MARKER 
 
TrxR1 is a selenoenzyme essential for maintaining the intracellular reducing state and 
is also participating in the cellular defense against oxidative stress. TrxR has a 
conserved penultimate C-terminal selenocystein (Sec) residue which plays an essential 
role in selenium metabolism. In the liver two main forms are expressed, one cytosolic 
form, TrxR1, and one mitochondrial form, TrxR2 [89-90]. Moreover, TrxR1 is 
involved in regeneration of important antioxidants such as ubiquinone, lipoic acid and 
ascorbic acid [91-93]. TrxR1 is also a key protein in cell proliferation and participates 
in DNA-synthesis [94].  
The role of TrxR1 in cancer was illustrated by the fact that TrxR1 removal by si-RNA 
mediated knockdown in lung cancer cells resulted in reversal of the neoplastic 
phenotype and inhibition of malignant characteristics. Tumour growth and metastasis 
was also drastically reduced in mice injected with TrxR1 knockdown tumour cells and 
a TrxR1 deficient cancer cell line has been shown to lose self-sufficiency in growth by 
S-phase progression defect and inhibition of DNA polymerase expression, which is 
essential for DNA replication [95]. Being a selenoenzyme, TrxR1 is dependent on 
sufficient supply of selenium for its own synthesis and functional status and for the 
synthesis of all other selenoenzymes. TrxR1 has been implicated in the pathogenesis of 
a multitude of diseases with special emphasis on cancer development and drug 
resistance [96-97]. TrxR1 has been suggested to be constitutively over expressed in 
many human cancer forms including liver cancer. TrxR1 was also shown to be 3,5 fold 
over expressed in isolated liver nodules from a rat liver cancer model compared to the 
activity in normal liver tissue, but with the same sub cellular distribution pattern [98].  
Our preliminary and unpublished studies of human chronic liver disease showed that 
the TrxR1 marker was not expressed in the hepatocytes in any of the activity stages of 
the inflammatory response. Neither was it expressed in fibrotic or cirrhotic livers with 
the exception of focal areas of proliferation, regarded as regenerative foci, but with a 
probable preneoplastic potential.  
Consequently, in our experimental rat liver tumour   model, we showed that TrxR1 was 
constitutively over expressed in preneoplastic liver nodules during promotion and in 
neoplastic nodules during progression [98-99]. TrxR1 therefore seemed to be a relevant 
marker for liver cancer and liver cancer prestages with a risk for malignant 
transformation. It was not clear if TrxR1 over expression in neoplasia was strictly 
related to growth rate or if it could be regarded a tumour specific marker.  
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6 SELENIUM 
 
Selenium is a most interesting and at the same time the most controversial trace 
element. Selenium is thought to maintain the equability of human health condition. The 
Swedish chemist Jöns Jakob Berselius discovered selenium in 1817. He first thought it 
was Tellurium, another related element named after the earth, but eventually realized 
that it was a unique element that he named after the moon. Selenium has similar 
chemical properties to sulfur and exists in five different valence states, -2, 0, +2, +4 and 
+6. Inorganic selenium can exist in the forms of selenite, selenate and selenide differing 
in their oxidation states. Selenomethionine (SeMet) and selenocysteine (Sec) and 
selenomethylselenocysteine (SeMSC) are the examples of organic forms of selenium.  
The selenium content in the soil varies greatly depending on geographical location and 
mineral composition. Consequently, selenium content in the food can vary as selenium 
enters into food via plants. The plants absorb Se from the soil as inorganic Se, 
selenate(SeO₄²ˉ) and selenite (SeO₃²ˉ) , and incorporate selenium in a number of 
organic forms, SeMet, Sec and SeMSC [100].  
During the thirteenth century, Marco Polo observed that certain plants consumed by his 
horses caused theirs hoofs to drop off during his journey in Asia [101]. The plants were 
recognized later as the most selenium rich plants, Genus Astragalus. Astragalus 
transforms selenium  mainly into the form of SeMSC [102].  
The major intake of selenium in human comes from consumption of bread, cereal, fish, 
meat, poultry, seafood and grain products [103]  and also through drinking water as 
inorganic selenate and selenite.   
 
6.1 SELENIUM METABOLISM 
The molecular metabolism of several selenium compounds and their relation to 
anticarcinogenic action has been extensively investigated. The main selenium form in 
the body is selenocysteine (Sec). Selenium is taken in via the food in an organic form, 
preferentially SeMet, which can be converted into Sec within the body. The inorganic 
and organic selenium is metabolized differently in the body, but with selenide as a 
common key metabolite, as it represents a branch point of two metabolic pathways, 
selenoprotein synthesis and excess selenium excretion [104]. (See fig3) 
In the presence of  glutathione (GSH), the inorganic, selenate is reduced by thioredoxin 
(Trx) or glutaredoxin (Grx) systems into selenite, which  in turn is reduced by these  
systems and other thiols into selenide [105]. In addition, selenite can be reduced by free 
cysteine non-enzymatically. Moreover, selenite is reduced to HSeˉ,via an intermediate 
glutathione conjugate GSSeSG  in the presence of GSH [106-107]. The organic 
selenium compounds, Sec and SeMSC are cleaved by β-lyase to selenide and 
methylselenol respectively [108]. Methylselenol in turn is converted to selenide by 
demethylation [109]. The common key metabolite of all absorbed selenium, hydrogen 
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selenide provides Se for synthesis of all selenoproteins via activation to 
selenophosphate [110].  
Selenide can be methylated into excretory metabolites and eliminated via urine and 
feces but also exhaled as volatile compounds via the lungs [111-112]. Urinary excretion 
of Se is the major route of excretion and the amount of excreted Se is closely related to 
dietary intake.  The exhalation pathway is considered to be the route of excretion when 
Se is ingested in high, toxic doses. Selenium is excreted in the urine mainly in the form 
of selenosugar and during excess selenium supplementation as thrimethylated Se, 
thrimethylselenonium ion (TMSe) [113], while, dimethylated Se, dimethylselenide is 
exhaled via the lungs. In addition demethylation may take place and convert the organic 
selenium back into inorganic forms. 
Selenium is usually absorbed effectively, but depending on the route of administration 
selenium uptake varies as in oral administration, a certain amount of selenium has 
already reacted with constituents of food in contrast to intravenous administration. 
Selenium is distributed in the body via the blood, but the affinity for selenium differs in 
different tissues.  In this selenium hierarchy liver tissue represents the tissue with the 
third highest affinity after skeletal muscles [114], whereas brain tissue is the tissue with 
the highest demand for selenium. In situations with selenium insufficiency the brain 
will conserve selenium most effectively [115-116].  
 
 
Fig 3. Schematic presentation of selenium metabolism. 
Inorganic sodium selenite metabolic pathways highlighted with thick arrows. 
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6.2 SELENIUM AND HEALTH  
Selenium is a trace element and dietary micronutrient essential for life. The 
physiological effects of selenium can vary from essentiality to toxicity, depending on 
the used chemical forms and doses. 
In human, 25 selenium containing proteins have been identified with important roles 
for various physiological functions. The recommended daily intake of selenium based 
on the selenium concentration sufficient for saturation of the selenoprotein 
glutathione peroxidase  (GPx) is  55µg Se per day for healthy adults [117].  During 
pregnancy and breastfeeding, the dose should be increased by 10-20 µg/day. Both 
excess and deficiency of selenium leads to serious disturbances in human health. 
More than 40 selenium deficiency related conditions, diseases and disorders have 
been reported, including aging, arthritis, cardiovascular disease, immunodeficiency, 
diabetes, stroke, muscular dystrophy, neurodegeneration, reproductive disorders and 
cancer.  The serum selenium contents in cancer patients were shown to be lower than 
in cancer free individuals and selenium in serum could function as an indicator of 
increased risk to develop cancer [118-119].  
Absolute selenium deficiency is involved in two major known diseases, the Keshan 
disease and the Kaschin-Beck disease. These disorders are common among the 
population in areas with extremely low selenium soil contents, like parts of China and 
some other countries, with a daily intake of  selenium of 11µg or less [120]. The 
Keshan disease is a severe cardiomyopathy that affects children and women in 
childbearing ages. The Kaschin-Beck disease is a degenerative joint disease caused 
by oxidative damage to cartilage with deformation of bone structure and 
osteoarthropathy. Selenium deficiency can be caused by long term parenteral 
nutrition in immunosuppressed patients as well. Recently, selenium and 
selenoproteins have been shown to be involved in inherited defects. The diseases 
related to inborn defects of selenium utilization, transport, and metabolism is 
expanding, including inherited muscle disorders, growth retardation and neuro-
degenerative disorders [121].  
At the same time, in high doses, selenium is very toxic and can cause serious 
physiological disturbances and death. The maximal safe multiple oral dose of selenium 
in human is suggested to be 5µg/kg body weigth and the maximal single safety dose is 
50µg/kg body weight [122]. The symptoms of acute selenium intoxication is  garlic 
odour of breath, tachycardia, and respiratory disorders due to pulmonary oedema and 
ultimately  death.  Chronic selenium toxicity is manifested by morphological changes 
in fingernails and loss of hair [123].  
 
 
6.3 SELENIUM PREVENTION OF CANCER AND THE SUGGESTED 
MECHANISM OF ACTIONS 
 
The association between selenium and cancer have been studied in many 
epidemiological and prospective studies since a long time. An inverse relationship 
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between selenium content in food and blood and risk for cancer and related mortality 
rate is observed in many studies. The selenium serum level in cancer patients is lower 
than in control cancer free patients [118].  In more than 100 animal studies selenium 
preventive effects are reported and several human studies supported the results as well 
[124-126]. 
Nevertheless, the molecular mechanism of selenium tumour prevention is not yet fully 
elucidated. Several mechanisms so far have been proposed as possible selenium tumour 
preventive actions including anti-oxidant effects, mediated by selenoproteins, 
stimulation of DNA repair and induction of apoptosis in precancerous cells. Selenium 
in low concentrations is essential for growth but in moderate to high concentrations it 
might inhibit cell growth (See fig 4). 
In our  previous  studies we have been able to show that the effective tumour preventive 
doses of selenium are high, in a supranutritional dose range [99]. The metabolism of 
supranutritional and subtoxic levels of selenium in long term studies is therefore 
important to elucidate. 
 The exact function of the 25 selenoproteins found in the body is not known but groups 
of important redox active selenoproteins, including the thioredoxin reductase and 
glutathione peroxidase families are well studied [127-128]. 
  
Depending on the doses used and the chemical forms of selenium, selenium can affect 
cancer development in different ways and at different stages.  
The antioxidant role is suggested to be mainly preventive and affect the process also at 
very early precancerous stages.   Selenoproteins play a central role in upholding redox 
homeostasis and are involved in all three levels of antioxidant defence against ROS and 
reactive nitrogen species (RNS).  Affecting DNA integrity and repair organic selenium 
protects against oxidative stress.  Seo et al 2002 showed that SeMet induces DNA 
repair in normal human fibroblasts in-vitro. Furthermore, Mukherjee et al 2001 showed 
that SeMet was most effective in regulating of DNA chain break control and reduces 
aberrant crypt foci in the colorectal tissues of rats.  
In addition to detoxifying harmful ROS and RNS, selenium acts as a detoxifying agent 
by chelating metals like Au, Pt, Cd, Co and Hg [129-130].  Several of these metals can 
react and inhibit important proteins like thioredoxin reductase.  Moreover, selenium 
have been reported to prevent cadmium induced peroxidative damage and cancer 
development in  prostate and breast [131].  
 Furthermore, it became evident that selenium combat cancer progression by regulating 
several genes implicated in tumour progression, including phase II detoxifying 
enzymes, tumour suppressor genes and certain caspases [132-133].  Selenium have also 
been shown to regulate genes involved in cell cycle regulation in an inhibitory manner 
[134].  
The effect of selenium in late stages of cancer development and treatment is believed to 
depend on the prooxidative effects of selenium in high doses and on ROS production 
[135].  ROS, mainly superoxide produce oxygen radicals  and lead to cell death due to 
an intracellular  imbalanced oxidative status [136] . ROS, will interfere with the activity 
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of several important cell  signalling molecules, enzymes, tumour suppressors and 
transcription factors like, p53, AP-1, Sp-1, Nf-kB , ASK-1 and JNK [137-139]. The  
function of these proteins, in turn  is regulated by thioredoxin [140].  
A recent in-vitro study on selenium cancer specific toxicity revealed that the 
extracellular reducing environment established by the cancer cells enabled the specific 
selenium uptake by these cells [141]. Moreover, redox active metabolites of selenium 
have been demonstrated to induce apoptosis by different mechanisms of action. 
Selenide induces caspase independent apoptosis by activation of p38, p21 and p53 and 
generating DNA strand breaks. Monomethylselenol causes caspase dependent 
apoptosis by upregulating p21 and p16. In addition it is known that selenium 
compounds cause cell arrest at different phases of the cell cycle, for example selenite 
treatment leads to S-phase arrest, while monomethylselenol causes G1 arrest. 
Furthermore, these compounds also inhibit cell proliferation and growth by suppressing 
Erk, AR, Akt and cyclins and CDks [142-143]. An inverse relationship between 
resistance to conventional chemotherapy and sensitivity to selenite cytotoxicity was 
also observed.  In addition, selenium inhibits neoangiogenesis by down regulation of 
VEGF and counteracts metastasis by down regulating of osteopontin and collagen 
[144-145].  
 
 
Fig 4. Selenium concentration and suggested biological effect. 
 
 
 
6.4 SELENIUM IN CHRONIC LIVER DAMAGE AND LIVER CANCER  
 
Selenium has been proposed to have a liver cancer preventive effect. Prevention of liver 
cancer was reported from a population based study performed in China, in an endemic 
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area of chronic viral hepatitis and hepatocellular carcinoma. In a 5 year long study on 
selenium supplementation,the persons in  the selenium supplemented  group were 
provided  table salt fortified with sodium selenite which resulted in an additional 30-
50µg selenium ingestion daily, while the control groups was provided by ordinary table 
salt.    The incidence of HCC was reduced by 35%  in the selenium supplemented 
group compared to the control group  [124]. In a trial including exclusively HBsAg 
positive patients, 226 patients were provided either with 200µg selenized yeast or 
placebo tablets daily for four years.  Seven out of 113 patients in the placebo group 
developed HCC compared to none of 113 subjects  in the selenium group [125]. The 
interpretation of these results was that selenium inhibited the replication of hepatitis 
virus, which resulted in a sustained delay of HCC development.   One proposed 
mechanism of selenium tumour prevention in chronic liver diseases is that selenium 
causes apoptosis of cells in prestages of cancer while it is not affecting normal 
neighboring hepatocytes. Results from studies revealing selenium status in different 
liver diseases and their progression and severity of liver damage showed that the 
selenium level in serum and liver was reduced in all forms of chronic liver damages 
[146]. The same results was found in patientes with liver cirrhosis [147]. The reduction 
of serum selenium in cirrhotic patients was more pronounced than in patients with 
chronic hepatitis without cirrhosis. The results indicated an inverse relationship 
between the intensity of the hepatic injury and serum selenium levels. In children with 
liver cirrhosis, the serum level of selenium was also found to be significantly lower 
than in controls [148].  Selenium supplementation in experimental hepatic fibrosis 
induced by chronic carbon tetrachloride administration decreased the collagen fibers 
and the number of collagen producing stellate cells [149]. Serum selenium was also 
found to be decreased in alcoholic and nonalcoholic liver diseases [150].   
Selenium in supranutritional and subtoxic doses was shown to have a cancer preventive 
effect in rats. In our previous study on the DEN-induced hepatocarcinogenesis rat 
model selenium inhibited liver cancer development during both promotion and 
progression phases.  Numerous epidemiological studies have reported that the selenium 
level in cancer patients were lower than in cancer free subjects [151].  
One of the suggested mechanism of selenium tumour prevention is that selenium has a  
direct regulating effect on  the cell cycle progression and causes cell cycle arrest at G1, 
S-phase and G2 phases of the cell cycle [152]. If a direct acting effect on the cell cycle 
is of importance for liver tumour prevention in patients with chronic liver disease it is 
also of importance to consider the effect of selenium on the normal regenerating 
hepatocyte. Patients with chronic liver disease have an increased compensatory 
hyperplasia to compensate for the loss of hepatocytes in the disease. This hyperplasia is 
vital for the patients to maintain their functional liver mass. Consequently, it is 
important to compare the selenium effect on liver regeneration with that on dividing 
neoplastic cells.   This question is addressed in this thesis.  
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6.5 SELENIUM PREVENTION AFTER SURGICAL RESECTION IN HCC  
Due to the increased number of patients with HCV the incidence of liver cancer has 
been increased during the last decade in the United States and Europe. Improved 
surgical techniques and methods for early detection of liver cancer, including α-
fetoprotein measurements has increased the number of patients that have been offered 
the option of surgical resection. However intra hepatic tumours reappear within the first 
few years after resection in 80% of cases [153]. Within 2 years after primary resection 
the cancer usually relapses with multifocal and more aggressive multidrug resistant 
tumours. The relapse in HCC can occur in two different ways. Recurrent tumours can 
arise from invisible microscopic spread of cells from the initial tumour or from a new 
focus independent of the resected cancer in patients with chronic active hepatitis 
complicated with cirrhosis. Early relapse within one year after resection is likely to be 
derived from the initial tumour whereas late relapses can be related to development of  
a new tumour in the cirrhotic liver [153]. Strategies are needed to diminish the post 
operative early and late recurrences that could be caused by   different molecular 
mechanism acting at early carcinogenesis and late cancer spread and metastasis. 
Systemic chemotherapy is not effective in prolonging survival and is not well tolerated 
for its significant toxicities [154]. Micro vascular invasion and spread of tumour cells 
followed by formation of satellite tumour foci or nodules are the main predictors of 
tumour recurrence. The treatment strategy for recurrent disease is not well established 
and there is a need of novel approaches to improve the clinical outcome. Repeated 
hepatectomy may provide a 5-year survival of up to 50% but it is usually associated 
with high incidence of rerecurrence. The following second and third resections are 
considered to enable a better outcome compared to only a single resection strategy. 
Local ablative treatment of HCC recurrence show comparable results with reresection. 
Up to 60-70% of the recurrence after resection represent foci previously undetected in 
the liver after radical resection [46]. It is reasonable to suggest that treatment of the 
remaining tumour cells (Minimal Residual Disease, MRD) with tumour cell 
proliferation inhibitors will delay or inhibit relapse in patients after resection or 
transplantation. Many patients do not benefit from liver resection so therapies targeting 
the underlying liver disease must be used to improve the 5-year survival rate [155]. 5 
year survival rate after liver resection is 65 % and the underlying liver disease is the 
main factor important for long-term outcome of HCC. Interferon alpha and Interferon 
beta can inhibit the recurrence in HCV related HCC.  
Liver cancer is one of the most drug resistant tumours and the main reason for 
unsuccessful treatment with chemotherapeutic drugs in HCC is the chemo resistance of 
the tumour cells and the heterogeneity of the liver tumour. Based on experimental data, 
knowledge of the carcinogenic process and clinical experiences this resistance can be 
characterized as primary multi drug resistance (MDR). So far the attempts to fight 
MDR in liver cancer have been of limited success. Recent experimental in vitro data, 
however, suggest that sodium selenite in high dose levels sensitizes cancer cells to 
radiation therapy [156] and enhances the transition of drug resistance cells into drug 
sensitive. It is therefore intriguing to suggest that selenite could be used either alone or 
in combination with other drugs to treat drug resistant liver cancer, residual tumours 
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after therapy, MRD or disseminated tumour cells (DTC) and circulating tumour cells 
(CTC).  
 
 
6.6 TUMOUR PREVENTION IN CHRONIC LIVER DISEASES WITH CELL 
PROLIFERATION INHIBITORS 
 
Despite its enormous metabolic activity the liver is one of the most quiescent organs in 
entire organism with an only 1 per 10,000-100,000 cells that is in the cell cycle in any 
given time in an adult individual [157].  In chronic liver diseases, a sustained cycle of 
hepatocyte injury, cell death, inflammation and repair with coexisting fibrosis and cell 
proliferation take places, rendering an increased rate of cell proliferation, that in many 
cases are exceeding 1-2 %, i.e a 100-1000 fold the normal rate. In many acute or 
chronic and progressive liver diseases, ongoing liver cell damage leads to apoptosis and 
necrosis resulting in impaired liver function and associated morbidity. The 
compensatory cell proliferation is  essential to maintain hepatic function in chronic 
liver disease and to life [158].  
The regulatory mechanism of liver cell proliferation in chronic liver diseases is not 
fully explained. In management of liver cancer prevention it is important to reduce the 
activity of the underlying disease, particularly in chronic hepatitis caused by HBV, to 
prolong the expectancy of tumour free survival.  One of the dilemmas in cancer therapy 
is that normal rapidly dividing cells usually are affected by the anticancer therapeutic 
drugs, since chemotherapeutic drugs frequently target mechanisms involved in cell 
division. To overcome these difficulties, the researchers are challenged to discover 
more tumour specific and individually adapted treatment strategies. Drugs interfering 
with small molecular targets and antibodies directed against certain receptors and 
molecules in cell signaling cascades have been developed and tested in clinical phase II 
and III studies. Sorafenib is one of them and today the only FDA approved drug for the 
indication of treatment of patients with advanced HCC. Sorafenib targets several cell 
cycle kinases, particularly it inhibits neovascularization which is usually activated in 
liver cancer and of importance for tumour nutrition and spread. 
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7 AIM 
 
The aim of this experimental study concerns liver tumour prevention and uses animal 
models to form strategies based on the use of sodium selenite. The previous work on 
experimental hepatocarcinogenesis performed by the research group has shown that 
sodium selenite administered in the drinking water in a dose dependent way reduced 
the volume fraction of preneoplastic liver nodules in promotion and progression, but 
did not affect the initiation step. It was also clear in these studies that thioredoxin 
reductase, a selenium containing, selenium inducible enzyme was affected and induced 
in the process. The cytosolic thioredoxin 1, but not the mitochondrial thioredoxin 2, 
was heavily increased in liver nodules and cancers induced in the model. The doses of 
selenite that showed the best effect on tumour prevention were high and in the range 
where selenite was pro-oxidative and potentially toxic. 
The following questions were raised: 
- If selenite inhibits neoplastic growth, will it also inhibit regenerative growth in non-
neoplastic cells? 
- Is TrxR1 a constitutive tumour marker or an unspecific marker for cell growth? 
- Is it feasible to expose the rats for sodium selenite in tumour preventive doses in long-
term studies or will selenium eventually give rise to selenium toxicity, limiting its use 
in tumour prevention to patients with chronic liver disease? 
- What is the homeostasis of selenium upon long-term distribution of sodium selenite in 
tumour preventive doses? Will selenium accumulate in the body to toxic levels when 
selenium is administered during long time? 
- Is thioredoxin reductase 1 induced by tumour preventive doses of sodium selenite, and 
how is the kinetics of the induction. What is the relation between thioredoxin reductase 
activity and levels of sodium selenite? 
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8 RESULTS  
 
Paper I  
 
The effect of sodium selenite on liver growth and thioredoxin reductase 
expression in regenerative and neoplastic liver cell proliferation 
 
We have shown that selenium inhibit cell proliferation in a dose dependent manner in 
both preneoplastic and neoplastic liver lesions in a synchronized experimental model 
for hepatocarcinogenesis in the rat. In this study the effect of selenium in a tumour 
preventive dose on normal regenerative cell proliferation was compared to the effect on 
tumour progression in order to investigate selenium as a candidate for liver cancer 
prevention in chronic liver disease with chronic repair. We also studied the effect of 
selenium on the regulation of thioredoxin reductase in normal regenerating liver. 
Thioredoxin reductase is a redox active selenoenzyme that has been shown to be over 
expressed in preneoplastic and neoplastic liver lesions in the experimental rat model as 
well as in human hepatocellular carcinomas.  
Sodium selenite (5µg/ml) administrated in the drinking water to rats that was either 
partially hepatectomiced or sham operated did not affect the body weight or the gain of 
liver mass after 2/3 partial hepatectomy, although a slight delay of S-phase and mitosis 
was seen. Tumour growth studied as increase of tumour volume or mass during tumour 
progression was however significantly reduced by selenium. In non-neoplastic 
regenerating liver cells thioredoxin reductase mRNA was not affected by selenium, 
while the activity of the cytosolic enzyme was only transiently increased over the time 
of cell proliferation. Another interesting observation was that thioredoxin reductase 
during tumour progression was over expressed in comparison to the surrounding tissue 
only in the growing, persistent, precancerous lesions but not in the remodeling lesions 
where there was no sign of liver cell proliferation.  
We concluded that 5 µg/ml sodium selenite did not compromise liver cell proliferation 
after partial hepatectomy in an extent that affected liver regeneration and gain of mass. 
We also concluded that the neoplastic over expression of thioredoxin reductase could 
only partly be explained by the tumour growth rate. The discrepancies between TrxR1 
expression and tumour growth heterogeneity made us suggest that TrxR1 in fact is a 
constituent of the neoplastic phenotype.  
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PaperII  
 Selenium homeostasis and Induction of Thioredoxin Reductase in long term 
Selenium Supplementation in the rat. 
From our previous study it became clear that sodium selenite in supranutritional but 
subtoxic doses exerted tumour preventive effects. Consequently, in this study we 
wanted to investigate the long term effect of sodium selenite supplementation in tumour 
preventive doses, 1µg/ml and 5µg/ml.  
The kinetics of selenium uptake and accumulation and TrxR1 induction after treatment 
with sodium selenite in the drinking water in doses of 1µg/ml and 5µg/ml for 10 weeks 
were studied in young male Fisher rats. Long term selenite exposure via the drinking 
water caused a dose dependent increase of selenium levels in the blood and liver. This 
increase leveled out at 6 and 8 weeks, respectively, at the same level of selenium 
regardless of treatment and dose. Thus, there was no accumulation of selenium in blood 
and liver over time at chronic exposure. A selenium dependent increase of the activity 
of TrxR1 was also seen and was parallel with the selenium levels in the liver tissue, 
while an initial induction of TrxR1 mRNA was seen during the first two days of 
treatment, during which time the selenium levels in the liver was increasing. 
Discontinuation of selenite exposure did not result in significant reduction of neither 
selenium content nor TrxR1 expression levels during the following weeks and even at 
later time points. Sodium selenite at the dose levels of 1 and 5µg/ml did not affect body 
weight or relative liver mass. Thus we concluded that long term treatment of selenite 
did not cause accumulation of selenium or permanent changes of TrxR1 expression. 
 
 29 
 
9 COMMENTS ON METHODOLOGIES 
The details of the methods used are described in the individual papers included in this 
thesis. In this chapter I only comment on some methods used, particularly regarding the 
animal experimental models we used in this study. 
 
9.1 ANIMAL EXPERIMENTAL STUDIES 
In this thesis work we used two animal models, a rat liver model for 
hepatocarcinogenesis, the Resistance Hepatocyte model by Solt and Farber  [68] and a 
rat model for liver regeneration after 2/3 partial hepatectomy, first described by Higgins 
GM and Andersson RM [159]. 
9.1.1 The resistant hepatocyte model for hepatocarcinogenesis in the rat  
For the study of experimental  liver cancer  we used the Solt and Farber model [68] 
with slight modifications [160] .    
 
 
Fig 5. Solt and Farber model  
 
The resistant hepatocyte model allowed us to perform a consecutive study on tissues 
harvested from all three phases of liver cancer development, initation, promotion and 
progression. In this model, initation is performed using diethylnitroamine (DEN) in a 
necrogenic dose (200µg) and promotion using a combination of 2-acetylaminofluorene 
(2-AAF) and 2/3 partial hepatectomy. During promotion only the hepatocytes resistant 
to the mitoinhibitory effect of the promotor will be able to respond to the mitogenic 
signals after partial hepatectomy and grow. After termination of promotion, most of the 
lesions that appeared during promotion will stop growing and remodulate back to a 
normal looking liver phenotype. 
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In only 1% of the nodules changes will appear that gives rise to cells that expand 
clonally in the absence of the promoter and progress until the development of a 
malignant tumour. During this phase of carcinogenesis, the neoplastic growth is 
autonomous and not dependent on the selective pressure from a promoter inhibiting 
growth of the surrounding non-neoplastic hepatocytes. 
 
9.1.2 The liver regeneration model, 2/3 partial hepatectomy 
For the study of rat liver regeneration 2/3 partial hepatectomy was used. The method is 
reliable and easy to standardize as far as timing and relative amount of liver removed is 
concerned and the rats recover quickly from anesthesia and surgery. There are 
alternative methods described that use chemical hepatectomy, which are more difficult 
to reproduce. In this study we used 2/3 partial hepatectomy under inhalation anesthesia 
with Isopenthal in a nebulizer. After opening of the abdomen the median and the left 
lateral lobes were ligated with silk and removed. One group, drinking tap water, was 
compared to one group exposed to sodium selenite in the drinking water. Sham surgery 
was used as control. The sham surgery is described in paper I. 
 
9.2 IMMUNOHISTOCHEMISTRY AND LABELING INDEX 
Glutathione S transferase-π (GST- π) is usually considered as a marker for liver 
preneoplastic and neoplastic lesions in rat liver carcinogenesis as GST- π is not 
expressed in normal rat liver [161-162]   
GST- π staining was performed to localize preneoplastic and neoplastic liver lesions at 
3, 6, 9 and 12 months after DEN initiation.  GST- π is expressed in preneoplastic and 
neoplastic liver nodules and is considered a marker for the neoplastic process in the rat. 
GST- π is very low in normal rat liver and not induced by drugs, cell proliferation or 
expressed in fetal liver [163]. The limitation of the enzyme as a marker is that it is does 
not differentiate between preneoplastic, remodeling preneoplastic and neoplastic 
lesions, which are a limitation in studies of tumour progression. The S-phase specific, 
cell proliferation marker bromodeoxyuridine (BrdU) was administrated 3 days before 
the rats were extinguished and livers harvested.  BrdU-labeling index in GST- π, TrxR1 
and BrdU positive neoplastic lesions in selenium treated and non-treated rats were 
calculated in randomly selected image fields. The number of fields calculated was 
decided by determination of accumulated mean. At least 1000 hepatocytes were 
counted in each slide. For TrxR1 immunohistochemistry  we used a method described 
and verified before [99] . In this work we have used the term over expressed to indicate 
that the staining was more intense in for example a liver nodule to that in the 
surrounding tissue in the same slide. We have used immunohistochemistry as a way to 
visualize the relative presence of the epitopes on the proteins and not as an expression 
of increased enzymatic activity in absolute terms. The existence of isoenzymes cross 
reacting with the antibodies makes it hard to translate staining intensity into amount of 
active enzyme. Cell proliferation kinetics after PH in selenium treated and non-treated 
rats were detected by cell proliferation marker MIB-5, an endogenous marker that 
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covers all cell cycle phases. The number of mitotic figures was also counted in the 
slides.  MIB-5 and mitotic figures were counted in randomly selected image fields as 
above. 
  
9.3 ENZYME ACTIVITY MEASUREMENT  
The TrxR1 activity was measured  in  liver  tissue homogenates  by an enzyme assay 
according to Holmgren and Björnstedt [164]. In this assay, we used Trx from E.coli and 
insulin as substrates. The substrate specificity of mammalian TrxR1 is broad and it 
reduces thioredoxin from different species, including E.coli. The advantage to use Trx 
from E.coli is that, due to lack of regulatory Cys residues, E.coli Trx is stable and do 
not cause protein aggregation and inactivation due to oxidation. 
  
9.4 INDUCTIVELY COUPLED PLASMA MASS SPECTROMETRY  
The measurement of selenium in blood or liver is the most accurate way to assess 
selenium status. For the measurement of selenium levels in serum and in the 20% 
particle-free liver cytosol samples, Inductively Coupled Plasma Mass Spectrometry 
(ICP-MS), an analytical method for the quantitative determination of total selenium, 
was used [165]. In brief, the samples were digested in nitric acid using microwave-
assisted digestion at 70 bar and 220°C. Following dissolution, the solutions were 
diluted with water, and the selenium concentration was determined by ICP-MS using 
the 
78
Se isotope and by making use of the dynamic reaction cell of the ICP-MS for 
removal of the argon dimer interference based on the specific mass to charge (m/z ) 
ratio. 
ICP-MS is applied for detection and quantification of a wide range of sample types and 
the method is considered to be sensitive and reliable for detection of trace elements in 
biological samples. Moreover, the required sample size is small. The unique feature of 
ICP-MS is to decrease the polyatomic ions, by chemically removing them out of the 
ion beam before the analysis. The detection limit of ICP-MS for selenium is below 
50-100 ppt (parts per trillion, 10
12
) 
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10 GENERAL CONCLUSION  
 
In this thesis rat liver models were use to study the effect of sodium selenite on  tumour 
growth and neoplastic cell proliferation and compare that to the effect on regenerative 
liver cell proliferation and gain of liver mass after partial hepatectomy. We also studied 
the selenium homeostasis and induction of thioredoxin reductase during long term 
supplementation to normal rats. 
We concluded that sodium selenite reduced the rate of volume expansion of neoplastic 
lesions during progression up to 12 months after promotion and that the rate of cell 
proliferation in the lesions was lower in the rats treated with sodium selenite. On the 
contrary sodium selenite did not affect the rate of liver mass expansion after 2/3 partial 
hepatectomy and did not significantly reduce the rate of cell proliferation after partial 
hepatectomy.  
Thioredoxin reductase (TrxR1) was over expressed in the neoplastic liver lesions in 
comparison to the surrounding tissue. TrxR1 did increase during cell proliferation after 
partial hepatectomy with a peak activity at the time when the MIB 5 marker and mitotic 
index showed that the cells were dividing. After that the enzyme activity declined to 
background activity, although gain of liver mass was still going on for several days. 
This increase in enzyme activity was further potentiated by sodium selenite. It is 
therefore possible that at least a part of the neoplastic over expression of TrxR1 could  
be explained by the fact that the tumour cells were growing. The fact that remodelling 
liver nodules, positive for the classical liver nodule marker GST-π, but negative for 
BrdU, were negative also for TrxR1 during late progression could support this 
conclusion. However, we believe that TrxR1 in addition to be increased during cell 
proliferation, was a constitutive tumour marker based on the following observations 
from our immunohistochemical studies. The TrxR1 immunohistochemical signal in the 
nodules was strong and homogeneous within the lesions and the intensity of the signal 
was not correlated to the rate of cell proliferation, measured as BrdU-index, or to the 
distribution of growing cells in the nodules. The increase of TrxR1 activity during 
regenerative growth could not be detected by immunohistochemistry, with the 
exception for a very brief period 24 h after partial hepatectomy, when a periportal, zone 
1 , weak  immunohistochemical signal was seen in 2 rats of 4 in the group not treated 
with selenite. We have also noticed in a so far unpublished work that TrxR1mRNA was 
reduced by 5 µM selenite in advanced rat liver cell carcinomas, which indicate a 
different response to selenite in neoplastic cells in comparison with normal and 
regenerating cells where TrxR1 mRNA is transiently increased.  
 
Selenium did not accumulate in serum or liver over time upon long-term exposure to 
sodium selenite. After an initial increase of the selenium content in serum and liver a 
steady state equilibrium was established at a selenium level that was independent on the 
given dose of sodium selenite in the serum but slightly higher in the liver in the high 
dose group indicating a balance between selenium uptake and elimination. TrxR1 
activity was following the selenium levels in the liver, but TrxR1 mRNA was only 
induced at the time when the selenium levels in serum and liver were increasing. 
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During a 10 week period of selenite supplementation at tumour preventing doses no 
signs of toxicity was observed. Nor did the rats drinking tap water with 5µg/ml sodium 
selenite subjected to hepatectomy or sham operation show signs of toxicity. 
Based on our experimental results we propose that sodium selenite is a good candidate 
for tumour preventive treatment in patients with chronic liver disease and increased 
cancer risk under long time, without suppressing the life-essential compensatory liver 
regeneration. 
We also suggest that the selenoenzyme, thioredoxin reductase 1 could be used as a  
histological marker for preneoplasia and neoplasia in chronic liver disease. 
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11 GENERAL DISCUSSION AND FUTURE 
PERSPECTIVES 
 
The work that has been performed in the rat liver model on selenium prevention of 
hepatocarcinogenesis shows that sodium selenite influences the carcinogenetic process 
in a direction that reduces the cancer risk. Based on the data from the animal model 
sodium selenite can also be used for long-term treatment at supranutritional and pro-
oxidative doses without accumulation of selenium and severe side effects. It is 
therefore reasonable to assume that sodium selenite has a liver tumour preventive 
effect. The differentiated effect of sodium selenite on neoplastic and regenerative liver 
cell proliferation allowing regenerative growth while the growth of tumour cells are 
reduced is also beneficial for tumour prevention in a situation where regenerative cell 
proliferation and repair is requested.  
It is also an advantage that selenite is effective in reducing growth of preneoplastic liver 
lesions during promotion as well as of neoplastic lesions in early progression. Our 
interpretation is that a selenite preventive strategy could be designed for secondary 
prevention delaying malignant transformation and for tertiary prevention reducing 
growth of established HCC. 
Although the experimental studies are promising we do not know if selenite has the 
same effect in humans and at what doses we could expect a clinical effect. However 
based on existing data from human prevention studies [124-126] we believe that 
selenium could be given to healthy humans in doses of 200 to 300µg per day for a long 
time without side effects. But the knowledge of the effect of selenite given to humans 
with a chronic liver disease is limited as is information on the interaction of selenite 
with other treatments interfering with the immunsystem or being cytotoxic. In 
collaboration with the infectious clinic at Karolinska University Hospital Huddinge we 
have designed a clinical intervention study on patients with chronic hepatitis B and 
hepatitis C that are resistant to conventional therapy or that has failed on conventional 
therapy due to side effects. Initially we want to evaluate the effect on the activity of the 
hepatitis after one year, but our aim is also to be able to evaluate the effect on cancer 
risk in a long-term study. We are also investigating the prerequisites for doing this 
study in Mongolia, where viral hepatitis and HCC is much more frequent, making it 
easier to find patients to include in the study. NASH is another diagnosis of interest for 
selenium tumour prevention. 
Another very interesting clinical application for selenite in tertiary prevention is to give 
selenite to HCC patients before and after radical surgery with the aim to reduce 
activation, growth and establishment of manifest metastasis from remaining cancer 
cells. Early relapse of HCC in the liver or outside the liver is the major cause of death 
after surgery and most relapses from metastasis occurs within the first two years [166-
168]. 
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 The selective growth inhibiting effect of selenite on the tumour cells but not on the 
normal cells makes selenite a suitable drug that could be given already during the post 
operative phase of liver regeneration after surgery. At this time we have reasons to 
believe that the regenerative growth factors released vigorously could stimulate also the 
growth of the remaining tumour cells. Sodium selenite as an adjuvant treatment to 
patients with liver cancer that cannot be treated with radical surgery, with the purpose 
of reducing tumour growth and progression is an interesting option, but needs further 
clinical studies on doses and drug interactions. The potential of treating drug resistant 
tumors with toxic doses of selenium is certainly of interest and could have a potential to 
override the drug resistance of the tumour cells making them sensitive to selenite 
toxicity but also to other cytotoxic substances to which the tumour earlier has been 
resistant or to radiation. The use of toxic doses of selenite for treatment of resistant 
disease is supported by experimental studies on human cells [169-170] and in clinical 
trials [124-125]. 
In our work we have shown that the redox enzyme thioredoxin reductase 1 is affected 
by sodium selenite in tumour preventive doses and we do not exclude that TrxR1 might 
be a target in selenium tumour prevention. TrxR1 activity was induced by sodium 
selenite and reflected the tissue levels of selenium. TrxR1 mRNA was transiently 
increased over background only when the selenium levels were increasing but not 
during selenium steady state conditions even if the activity of the enzyme was 
increased. TrxR1 activity was also increased in S-, G2- and M phase in the cell cycle 
during liver cell regeneration and this activity was increased by selenite. TrxR1 was 
shown to be over expressed over surrounding in liver cancer in humans as well as in the 
rat liver tumour model. In the synchronized and sequential experimental model we 
could also show that TrxR1 was over expressed in the preneoplastic expanding clones 
during promotion as well as in growing neoplastic lesions, with a high risk of malignant 
transformation, during progression. We could therefore use TrxR1 as an immuno-
histochemical marker for liver preneoplasia, liver neoplasia and cancer risk. Such a 
marker is of potential clinical value for patients with chronic liver diseases 
accompanied with a high risk for liver cancer. Today, in the absence of a reliable 
marker, these patients can only wait for the cancer to appear. The limitation of TrxR1 
as a marker for liver cancer and cancer risk is that it is only established as a tissue 
marker that needs liver biopsies for evaluation. A plasma or serum marker would be of 
much greater clinical value. We have made efforts to measure TrxR1 in serum in the rat 
model but so far we have failed to find the enzyme protein or to measure the activity in 
serum. 
In so far not published work on human liver biopsies from patients with HBV and HCV 
viral hepatitis with different grades of necro-inflammatory activity as well as at 
different stages of liver fibrosis we have concluded by TrxR1 immunohistochemistry 
that the enzyme is neither over expressed in the hepatocytes in relation to the grade of 
inflammation nor the stage of fibrosis. Interestingly, however, foci of hepatocytes with 
aberrant organization, oriented in multi cellular cores or acini, were positive for the 
TrxR1 marker. This foci, or rosettes, were also shown by MIB-1 immuno-
histochemistry to be proliferative foci. It is intriguing to consider these lesions as 
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preneoplastic foci and indicators of the increased cancer risk in these livers. To address 
this question a more extensive clinical study of redox proteins in liver cancer using 
material from the liver sample collection at the pathology clinic is on its way. 
 
Our work support the conclusion that sodium selenite is an interesting candidate for 
liver cancer prevention that should be explored in humans. It has a low toxicity at 
tumour preventing doses and can be given as a lifelong treatment to patients with 
chronic liver diseases. It is cheap, easily available and simple to administrate. It is 
therefore attractive to suggest that sodium selenite tumour prevention should be 
explored also in countries outside the western world, with a low socio-economic status 
and where chronic liver diseases and liver cancer is much more common and a 
dominating cause of death in the population, even at young age. A future perspective of 
this work for me is therefore to collaborate with the authorities and the health care in 
my home country, Mongolia, to establish a clinical research program for the use of 
sodium selenite in secondary and tertiary liver cancer prevention. Such a program could 
be performed at the university hospital in Ulaanbaatar in collaboration with Karolinska 
Institutet, supported by grants from the Mongolian and Swedish governments in a 
collaborative effort as well as by research grants and resources from the health care 
providers in Ulaanbaatar. 
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